



## Trial Information Summary

|  |  |
|--|--|
| <b>ALLG Trial Number:</b>              | NHL26  |
| <b>Trial Name:</b>                     | A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid consolidation added to Rituximab maintenance therapy in those remaining PET positive   |
| <b>Lay Summary:</b>                    | <p>Follicular lymphoma is the most common type of slow growing non Hodgkin lymphoma. Treatments and outcomes have improved considerably in the last 10 years with the introduction of the drug, rituximab to standard chemotherapy treatments. However, the disease returns repeatedly in many patients. PET scanning is a type of test used by doctors to outline where the lymphoma is in the body. PET scans will 'light up' the areas of active follicular lymphoma. Such positive PET scans after the end of treatment indicate that it is likely the lymphoma will return soon. This study is for patients with returned disease who have already received treatment again and so are at even higher risk of disease returning yet again. Patients will receive rituximab and up to 24 months of another drug, lenalidomide, which is designed to help the body's own immune system to keep the lymphoma away. The study will decide if the extra treatment with lenalidomide can change the scan result to negative and improve patient outcomes.</p> |
| <b>Participating Hospitals:</b>        | 1. Concord / 2. Gold Coast / 3. Orange Health / 4. Peter MacCallum / 5. Prince of Wales / 6. Princess Alexandra / 7. Royal Darwin / 8. Royal Hobart / 9. Royal Melbourne / 10. Royal Prince Alfred / 11. Shoalhaven / 12. St George / 13. Western Health / 14. Wollongong  |
| <b>Target Accrual (International):</b> | n/a  |
| <b>Target Accrual (ALLG):</b>          | Approx. 80 (16 PET+)   |
| <b>Expected Final Accrual Date:</b>    | November 2015  |